Full Press Release Details
Ronald Levy, M.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. He is also the Associate Director of Translational Science for the Stanford Cancer Institute. For more than 25 years, Dr. Levy’s research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab, the first FDA-approved antibody for the treatment of lymphoma. Dr. Levy holds an A.B. in Biochemistry from Harvard University and an M.D. from Stanford University.